The Rationale and Design of the Antihypertensives and Vascular, Endothelial, and Cognitive Function (AVEC) Trial in Elderly Hypertensives with Early Cognitive Impairment: Role of the Renin Angiotensin System Inhibition

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

| Citation          | Hajjar, Ihab, Meaghan Hart, William Milberg, Vera Novak, and Lewis Lipsitz. 2009. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. BMC Geriatrics 9:48. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1186/1471-2318-9-48                                                                                                                                                                                                                                                                                                      |
| Citable link      | http://nrs.harvard.edu/urn-3:HUL.InstRepos:4515094                                                                                                                                                                                                                                                                              |
| Terms of Use      | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP.                                                                                                                                 |
Study protocol

The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition

Ihab Hajjar*1,2,3, Meaghan Hart2, William Milberg1,4, Vera Novak1,3 and Lewis Lipsitz1,2,3

Address: 1Harvard Medical School, Boston, MA, USA, 2Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA, 3Division of Gerontology, Beth Israel Deaconess Medical Centre, Boston, MA, USA and 4GRECC VA Boston Healthcare, Boston, MA, USA

Email: Ihab Hajjar* - ihabhajjar@hrca.harvard.edu; Meaghan Hart - meaghanhart@hrca.harvard.edu; William Milberg - william_milberg@hms.harvard.edu; Vera Novak - vnovak@bidmc.harvard.edu; Lewis Lipsitz - Lipsitz@hrca.harvard.edu

* Corresponding author

Abstract

Background: Prior evidence suggests that the renin angiotensin system and antihypertensives that inhibit this system play a role in cognitive, central vascular, and endothelial function. Our objective is to conduct a double-blind randomized controlled clinical trial, the antihypertensives and vascular, endothelial, and cognitive function (AVEC), to compare 1 year treatment of 3 antihypertensives (lisinopril, candesartan, or hydrochlorothiazide) in their effect on memory and executive function, cerebral blood flow, and central endothelial function of seniors with hypertension and early objective evidence of executive or memory impairments.

Methods/Design: The overall experimental design of the AVEC trial is a 3-arm double blind randomized controlled clinical trial. A total of 100 community eligible individuals (60 years or older) with hypertension and early cognitive impairment are being recruited from the greater Boston area and randomized to lisinopril, candesartan, or hydrochlorothiazide ("active control") for 12 months. The goal of the intervention is to achieve blood pressure control defined as SBP < 140 mm Hg and DBP < 90 mm Hg. Additional antihypertensives are added to achieve this goal if needed. Eligible participants are those with hypertension, defined as a blood pressure 140/90 mm Hg or greater, early cognitive impairment without dementia defined (10 or less out of 15 on the executive clock draw test or 1 standard deviation below the mean on the immediate memory subtest of the repeatable battery for the assessment of neuropsychological status and Mini-Mental-Status-exam >20 and without clinical diagnosis of dementia or Alzheimer's disease). Individuals who are currently receiving antihypertensives are eligible to participate if the participants and the primary care providers are willing to taper their antihypertensives. Participants undergo cognitive assessment, measurements of cerebral blood flow using Transcranial Doppler, and central endothelial function by measuring changes in cerebral blood flow in response to changes in end tidal carbon dioxide at baseline (off antihypertensives), 6, and 12 months. Our outcomes are change in cognitive function score (executive and memory), cerebral blood flow, and carbon dioxide cerebral vasoreactivity.
Discussion: The AVEC trial is the first study to explore impact of antihypertensives in those who are showing early evidence of cognitive difficulties that did not reach the threshold of dementia. Success of this trial will offer new therapeutic application of antihypertensives that inhibit the renin angiotensin system and new insights in the role of this system in aging.

Trial Registration: Clinicaltrials.gov NCT00605072

Background

In addition to its role in developing cardiovascular disease and stroke, hypertension is also a risk factor for cognitive impairment [1-5] Although blood pressure tends to decline around the time of onset of clinical cognitive impairment[3], hypertension leads to accelerated decline in those with cognitive impairment or dementia[6,7] Of all the cognitive domains, executive function is more vulnerable to the effects of hypertension [8-10] Executive function is defined as the set of cognitive skills that are responsible for the planning, initiation, sequencing, and monitoring of complex goal-directed behavior[11] Seniors suffering from executive dysfunction have significant impairment in following medical advise [12] and are more likely to develop disability[13,14] It is estimated that close to 30% of the elderly population have executive function abnormalities and are generally undetected[15,16] No prior research has evaluated the effect of hypertension treatment on executive function or specifically enrolled those with executive dysfunction.

The process by which hypertension can affect cognitive and executive function is not clear. It is likely to be, in part, related to the cerebral blood flow (CBF) regulatory system. This is supported by the evidence that lower CBF measured by Transcranial Doppler (TCD) is associated with progressive decline in cognitive function[17] For example, in patients with amnestic mild cognitive impairment, lower CBF was associated with a higher risk for converting to dementia[18] Further, abnormal cerebrovascular reactivity was associated with worsening cognitive decline in patients with Alzheimer’s disease[19] Hypertension is associated with a decrease in CBF over and above any effect of age [20-23] Hypertension also impairs neurovascular coupling[24] and vasoreactivity to CO₂, a measure of brain endothelial function[25] Taken together, this provides a rationale for investigating the role of CBF regulation in the relation between hypertension and cognitive function.

From a neuro-humoral standpoint, multiple systems may be involved in the relation between hypertension and cognitive function. However, a paucity of evidence point to the renin angiotensin system (RAS). Anatomically, angiotensin II (Ang II) and its receptors are located in neurons inside the blood brain barrier and in the cerebrovascular endothelial cells and circumventricular organs[26] Functionally, Ang II has been linked with cognitive function in animal models[27] In addition, Ang II also decreases cerebral blood flow[28] and impairs neurovascular coupling[29] in hypertensive patients.

Ang II impairs endothelial function, which has been linked to poor cognitive function and early Alzheimer’s disease [30-33] The role of the endothelium in cognitive function, aging and hypertension has gained much attention recently [33-38] Central endothelial function can be assessed indirectly by the response of CBF to changes in end-tidal CO₂[39] Ang II plays a critical pathophysiological role in impairing endothelial function, especially in those with hypertension[30-32,40] Therefore we are suggesting that hypertension is associated with RAS activation and endothelial function impairment that in turn are associated with abnormal CBF regulation and cognitive and executive function impairments.

Multiple observational and experimental studies, although not universally consistent, have shown that use of antihypertensives may provide cognitive protection in the elderly population[41] However, it is not known if they provide this effect solely by lowering blood pressure or via an additional class specific effect[42] Based on our suggested pathway from hypertension to cognitive impairment, we are hypothesizing that antihypertensives that inhibit the activity of RAS lower this risk beyond just lowering blood pressure. They also restore endothelial function and cerebral blood flow regulation leading to further cognitive protection.

Drugs that inhibit RAS include angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). ACEI block ACE and decrease Ang II production, whereas ARB block the angiotensin receptor type 1 but not type 2 [43,44] ACEI and ARB may be protective against cognitive and physical impairment in hypertensives [45-50] In an observational study of 1,220 Italian individuals with heart failure, treatment with ACEI was associated with improved cognitive performance[51] The Perindopril Protection Against Recurrent Stroke Study indicated that perindopril (ACEI) reduced the risk of incident cognitive impairment in those with a previous history of stroke[46] In the Cognition and Prognosis in the Elderly trial, treatment with candesartan (ARB) was associated with a lower rate of cognitive decline only in those...
with Mini-Mental Status-Examination Scores between 24 and 28 compared to placebo, but not the whole sample[52] Other antihypertensives such as diuretics and calcium channel blockers may increase RAS activity through increasing renin levels[53,54] Diuretics, which produce similar lowering blood pressure effect to ACEI and ARB, activate RAS. Studies suggest that diuretics do not demonstrate a cognitive protective effect [55].

In addition to their effect on cognitive function, animal and human studies have suggested that both ACEI and ARB are associated with improved cerebral hemodynamics[56,57] In spontaneously hypertensive rats, treatment with ARB was associated with improved cerebral autoregulation[58], reduction in CBF decline after middle cerebral artery occlusions,[59] and normalization of the production of nitric oxide[60] Treatment with candesartan or captopril (ACEI) was also associated with a smaller infarct size after middle cerebral artery occlusion[59] In addition, ARB has a specific anti-aging effect on the cardiovascular system. For example, losartan, but not diuretic-based antihypertensive treatments, reduced heart to body weight ratio in old but not young Wister-Kyoto rats[61] In humans, studies on the effect of ACEI or ARB on cerebral hemodynamics are scarce. Work by our coauthor, Dr. Lipsitz, demonstrated that ACEI, but not other antihypertensives, improve CBF and cerebral vasoreactivity in cognitively intact hypertensive older adults[62,63] ARB have also been found to improve cerebral autoregulation in hypertensive patients with strokes[64] and diabetes[65] Preliminary studies suggest that drugs that inhibit RAS improve endothelial function[66] For example, in hypertensive patients treated with a beta-blocker, switching to an ARB resulted in improved endothelial function, measured by flow mediated dilatation[67]

Of the two classes, recent studies have shown that ARB may be superior to ACEI or diuretics in providing neuroprotection and improving vascular function[45,64,68] Both type 1 and 2 angiotensin receptors are present in the brain and have opposing effects: type-1 leads to vasoconstriction, whereas type 2 receptor leads to vasodilatation, neuronal differentiation, apoptosis and axonal regeneration[69] ARB, but not ACEI inhibit the type-1 receptors leaving the type-2 receptors active. This may translate to greater cerebral dilatation and a superior protective effect. In fact, preliminary evidence suggests that ARB are superior to other antihypertensives in their ability to reduce the risk of stroke[70] They also provide greater anti-atherosclerotic effect; measured by intima-media thickness, compared to ACEI in elderly hypertensive individuals[71] Therefore, we hypothesize that ARB are superior to ACEI in their cognitive and endothelial function effect measured by TCD at the middle cerebral artery, which in turn is superior to HCTZ, a drug that activates RAS.

Our objective is to conduct a double-blind randomized controlled clinical trial, the antihypertensives and vascular, endothelial, and cognitive function (AVEC), to compare 1 year treatment of 3 antihypertensives (lisinopril, candesartan, or hydrochlorothiazide (HCTZ)) in their effect on memory and executive function, cerebral blood flow, and central endothelial function of seniors with hypertension and early objective evidence of executive or memory decline.

Methods/Design

Experimental design and participants

The overall experimental design of the AVEC trial is a 3-arm double blind randomized controlled clinical trial. A total of 100 community eligible individuals with hypertension and early cognitive impairment are being recruited from the greater Boston area. Evaluated at the cardiovascular research laboratory at the Institute for Aging Research, and then randomized to candesartan, lisinopril, or HCTZ (*active control*) for 12 months. Currently recruitment efforts include various community activities, faith-based community events, health fairs, advertisements, and mail out announcements. Figure 1 describes the flow from screening to study exit. The Institutional Review Board at the Institute for Aging Research at Hebrew Rehabilitation Center for Aged approved the study and all participants provide written informed consent.

Inclusion Criteria include

1. 60 years of older; (2) hypertension: defined as a systolic blood pressure (SBP) of 140 mm Hg or greater or diastolic blood pressure (DBP) 90 mm Hg or greater or receiving antihypertensive medications; (3) early cognitive impairment without dementia defined as executive impairment (measured by the executive clock draw test (CLOX)) [72] or early memory impairment (measured by the repeatable battery for the assessment of neuropsychological status) [73]. Both of these tests are brief (total of 15 minutes), have been validated in elderly populations and have standardized norms[72,74]

Exclusion criteria include

1. Intolerance to 2 of the study medications; (2) SBP >200/DBP >110 mm Hg if not on treatment or SBP > 180/DBP > 100 mm Hg if on antihypertensive therapy; (3) Mini-Mental-Status-exam (MMSE)<20 or a clinical diagnosis of dementia or Alzheimer's disease; (4) elevated serum creatinine or serum potassium at baseline; (5) receiving >2 antihypertensives; (6) Comorbid illnesses (congestive heart failure, diabetes mellitus stroke); and (7) inability to perform the study procedures.
Individuals who are currently receiving 1 or 2 antihypertensives are eligible to participate if the participant and the primary care provider are willing to taper their antihypertensives. The medication is tapered while carefully monitoring blood pressure using a standard protocol in our laboratory [63].

The intervention
The intervention is treatment with lisinopril, candesartan, or HCTZ. The goal of the intervention is to achieve blood pressure control defined as SBP < 140 mm Hg and DBP < 90 mm Hg. The starting dose is 10 mg increased to 20 mg then 40 mg of lisinopril; 8 mg increased to 16 mg then 32 mg of candesartan; and 12.5 mg increased to 25 mg of HCTZ. Titration occurs every 2 weeks until blood pressure is <140/90 mm Hg. If blood pressure is still not controlled, long acting nifedipine is added at 30 mg increased to 60 mg and 90 mg in 2 week increments. If still not controlled, a beta-blocker is added at 12.5 mg increased to 25 mg and 50 mg of long-acting metoprolol.

Randomization and blinding
The randomization is performed using computer generated random numbers leading to a random allocation sequence. This random allocation is performed at the central pharmacy at Hebrew SeniorLife. Both study personnel and participants are blinded to the group assignment.

Study phases
The following are the study phases:

(i) Screen: This includes: (1) informed consent, (2) 2 seated blood pressure measurements separated by 5 minutes, (3) executive function and memory assessments, and (4) inclusion/exclusion criteria assessment. Eligible participants are scheduled for the Baseline visit. If they are receiving antihypertensives, they are also given the automated blood pressure measurement machine. Instructions on using the machine, tapering the antihypertensives, frequency of measurements, a diary, and appropriate phone numbers are provided.

(ii) Baseline evaluation and randomization: during this visit, participants undergo blood pressure measurements, cognitive assessments, physical measures, and TCD procedures. Randomization to one of the 3 antihypertensive medications occurs after the baseline visit.

(iii) Follow up: Participants are then seen every 2 weeks until blood pressure control (<140/90 mm Hg) is achieved. During these visits, blood pressure measurements, medication adjustments and assessments of potential adverse events are completed. Participants are then followed for 12 months after achieving target blood pressure (<140/90 mm Hg) and evaluated at 1, 3, 6, and 12 months. At each evaluation, blood pressure, adverse events, pill count (to assess compliance), use of other medications is assessed, and blood samples are drawn as outlined in Table 1. A re-evaluation including cognitive assessment, physical measures, TCD, and medical examination are performed at 6 and 12 months.

Experimental Procedures and measures
(i) Health Interview and exam: Demographics, social history and habits, family history, medication inventory[75], physical activity using the Physical Activity Scale for the Elderly[76] and Instrumental Activities of Daily Living (IADL) [77] data will be collected. Blood pressure is meas-

Figure 1
Study flow of the AVEC trial from the screening to the study exit.
ured using standardized procedures according to the American Heart Association guidelines[78,79]: the participant is in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and use of the bell of the stethoscope or an automatic calibrated blood pressure machine. The systolic blood pressure is defined as the pressure corresponding to the first korotkoff sound (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure is measured in both arms and recorded. The arm with the higher blood pressure is used throughout the study. Two blood pressure readings are performed at each visit and averaged per visit.

(ii) Neuropsychological assessment: The battery of tests we chose for both screening and for the outcome measures was selected with the following considerations: brevity, validation in a similar elderly population, and sensitivity to detect impairment change over the study period.

The screening tests include: the executive clock draw test part 1 (CLOX1) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) immediate memory domain. We selected the CLOX1 as a screening tool to detect those with executive function abnormalities. The subject draws a clock in response to the examiner's request. CLOX1 is sensitive to detect executive function[72] It has high internal consistency (Cronbach’s alpha = 0.82) and high between-rater reliability (r = 0.94, p < 0.001)[72] A score 10 or less on CLOX1 is required for eligibility[72] The RBANS immediate memory domain is a brief test to assess memory [74]. Participants are asked to repeat a list of 10 words and to repeat a short story. The reliability coefficient is 88% for the immediate memory domain. Those who score 1 standard deviation or below the age-education-specific standardized mean on this test will be eligible for the study. The Mini-Mental-Status-Examination (MMSE) is used to exclude participants with more advanced cognitive impairment. We selected this test since those who score 20 or less are more likely to have advanced cognitive impairment and dementia [80]. The inter-rater reliability of MMSE is 0.83[81]

The study outcome cognitive tests include Trail Making test (A and B), Hopkins Verbal Learning Test - Revised (HVLT-R), and the Digit Span Test. The Trail Making test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in an alternating sequence (B). This test is considered a benchmark of executive function. We selected this test because it is sensitive to detect frontal lobe pathology in patients with increased cerebrovascular and cardiovas-

### Table 1: Study procedures at various stages of the AVEC trial

| Visit          | Screen | Enrollment | Baseline | Titrate* | Follow-up |
|---------------|--------|------------|----------|----------|-----------|
| Months        | 0      | 2-4 weeks  | 1        | 2-3      | 3 6 12    |
| Informed Consent/Eligibility | X      | X          |          |          |           |
| Medication Inventory | X      | X          | X        | X        | X X X     |
| Weight/Height | X      |            |          |          |           |
| Blood pressure (2 every 5 min) | X      | X          | X        | X        | X X X     |
| Psychological Assessment | X      |            |          |          | X X       |
| Cerebrovascular Assessment |          |            |          | X        | X X       |
| Biochemical Measures | X      |            |          | X        | X X X     |
| Renin/Aldosterone |          |            |          |          | X X       |
| Adverse Events Screening |          |            |          |          | X X X     |

If a titration of medication needed baseline will be performed after titration and before randomization.
8% CO2 [88] followed by hyperventilation. CBF, blood measured by asking participants to deeply breath air with changes in sitting and standing positions. Vasoreactivity is blood pressure and heart rate in response to postural assess autoregulation by measuring continuous CBF, Finapress system and EKG[87] The Sit-to-Stand is used to heart rate and blood pressure are also measured by the

(ii) Cerebral Blood Flow and its regulation: CBF autoregulation and cerebral vasoreactivity are assessed by TCD using standard procedures described previously[85] Blood flow velocity, and hence CBF, is measured at the middle cerebral artery, which has a high correlation coefficient (0.995) with invasive blood flow measurements and high reliability in elderly subjects [86]. Beat to beat heart rate and blood pressure are also measured by the Finapress system and EKG[87] The Sit-to-Stand is used to assess autoregulation by measuring continuous CBF, blood pressure and heart rate in response to postural changes in sitting and standing positions. Vasoreactivity is measured by asking participants to deeply breath air with 8% CO₂ [88] followed by hyperventilation. CBF, blood pressure, and heart rate are continuously measured during hyper and hypocapnea. The change in CBF relative to the change in mean arterial pressure between sitting and standing is used to measure autoregulation. The slope of the relation between cerebrovascular conductance (mean CBF/mean arterial blood pressure) for each R-R interval and end-tidal CO₂ is used to assess CO₂ vasoreactivity [88].

(iv) Biochemical measurement is done to monitor for adverse events: hyperkalemia and renal failure. RAS activity is assessed using plasma renin activity and aldosterone levels[89] Plasma aldosterone is measured by a radioimmunometric assay (RIA). The Coat-A-Count procedure is a solid phase radioimmunoassay, based on aldosterone specific antibody immobilized to the wall of the polypropylene tube. 125I-labelled aldosterone competes for a fixed time with aldosterone in the patient sample for antibody sites. The sensitivity of this method is 16 pg/mL and the precision is 4-10%[90]. Plasma renin activity is measured by competitive binding radioimmunoassay (RIA) using the GammaCoat plasma renin activity RIA kit. The determination involves an initial incubation of plasma to generate angiotensin I, followed by quantification of angiotensin I by RIA. This technique is highly sensitive to low levels of 0.01 ng/mL/hour and is precise to activity that is less than 10%[91] In addition, a blood sample is drawn for storage and DNA extraction for future genetic studies.

(v) Adverse events (AE): We are screening for potential adverse events through self-report by the participant or the next of kin. These include: dizziness, vertigo, light-headedness, weakness, swollen lip or tongue or both, hospitalizations, cough, falls, angioedema, renal insufficiency, and hyperkalemia with ACEI and ARB. Hypokalemia may occur with HCTZ (potassium will be supplemented). The incidence of cough with ACEI varies but 5% is the most commonly reported rate [92]. Angioedema is extremely rare and occurs in about 0.68% of patients treated with ACEI [93]. Screening for adverse events occurs monthly by phone and during each visit where measurements of serum potassium and creatinine are performed. Emergency contact is also provided in case adverse events occur in-between visits or communications with the study personnel.

Statistical methods
All analyses will follow the intention-to-treat principle. We will use Mixed Models since we have correlated repeat observations and this procedure is not significantly affected by missing data[94,95] We will compare the change in the cognitive or CBF outcomes from baseline to 12 months between the three groups. The primary independent variable is group assignment (candesartan, lisinopril, or hydrochlorothiazide). A sample size of 100 will allow us to successfully complete at least 90 (10% drop out, 30 per group) participants. A 30 per group (90 total sample size) allows us to detect at least between group differences in the change (from baseline to 12 months) of 0.46 standard deviation units (α = 0.05; power 80%). Figure 2 provides results of power analysis for the detectable difference, sample size and power. Analysis for the safety of the intervention will be conducted by comparing the number of adverse events (cough, angioedema, leukopenia, increase in serum creatinine by more than 1 mg/dl, hyperkalemia (> = 5.5 meq/dl), hypotension (SBP < 100), dizziness, falls and hospitalization) and the number of participants who withdrew from the study in the three groups using Analysis of Variance (ANOVA).

Discussion
Aging of the population will lead to increase prevalence of hypertension and cognitive difficulties. To date, there are no available data to provide guidelines for treatment of hypertension in those with cognitive impairment. The AVEC trial is the first study to explore impact of antihypertensives in those who are showing early evidence of cognitive difficulties that have not reached the threshold of dementia. Observational studies have been conflicting and some suggest that treatment of hypertension may
have a negative effect on cognitive function [96-98]. Therefore, a carefully performed clinical trial that selects the appropriate population to study is critical to answer the question about the impact of antihypertensives on cognitive function.

The role of the RAS in aging is important because of the available therapeutic intervention for this system. Recently, RAS is a critical system in vascular biology and recently in neuroscience. Identifying an impact of ACEI orARB on cognitive or cerebrovascular function will provide additional mechanistic and therapeutic evidence of the role of RAS in aging.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
IH, LL and WM were involved in developing the basic idea for the study. VN was further involved in developing the idea and the transcranial Doppler and antihypertensive taper protocols. IH and MH are responsible for the data collection. All authors contributed to the final manuscript by reading and correcting draft versions.

Acknowledgements
Dr. Hajjar and the AVEC trial are supported by grant 1 K23 AG030057 from the National Institute on Aging.

References
1. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998, 31:780-786.
2. Paran E, Anson O, Reuveni H: Blood pressure and cognitive functioning among independent elderly. Am J Hypertens 2003, 16:818-826.
3. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. Jama 1995, 274:1846-1851.
4. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Soklo M, McGovern P, Folsom AR: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48.
5. Reinprecht F, Elmstahl S, Janzon L, Andre-Petersson L: Hypertension and changes of cognitive function in 81-year-old men: a 13-year follow-up of the population study "Men born in 1914", Sweden. J Hypertens 2003, 21:57-66.
6. Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004, 18:208-213.
7. Goldstein FC, Ashley AV, Freedman LJ, Penix L, Lah JJ, Hanfelt J, Levey AI: Hypertension and cognitive performance in African Americans with Alzheimer disease. Neurology 2005, 64:899-902.
8. Pugh KG, Kiely DK, Milberg WP, Lipsitz LA: Selective impairment of fronto-executive cognitive function in african americans with cardiovascular risk factors. J Am Geriatr Soc 2003, 51:1439-1444.
9. Saxby BK, Harrington F, McKeith IG, Wessely S, Ford GA: Effects of hypertension on attention, memory, and executive function in older adults. Health Psychol 2003, 22:587-591.
10. Kuo HK, Sorond F, Iloputaife I, Gagnon M, Milberg W, Lipsitz LA: Effect of blood pressure on cognitive functions in elderly persons. J Gerontol A Biol Sci Med Sci 2004, 59:M119-M119.
11. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rumman TA, Kauffer DI, LaFrance WC Jr, Coffey CE: Executive Control Function: A Review of Its Promise and Challenges for Clinical
Research. A Report From the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002; 14:377-405.

12. Royall DR, Cordes J, Polk M: Executive control and the comprehension of medical information by elderly retirees. Exp Aging Res 1997, 23:301-313.

13. Cahn-Weiner DA, Malloy PF, Boyle PA, Marran M, Salloway S: Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals. Clin Neuropsychol 2000, 14:187-195.

14. Royall DR, Palmer R, Chiiodo LK, Polk MJ: Declining executive control in normal aging predicts change in functional status: the Freedom House Study. J Am Geriatr Soc 2004, 52:346-352.

15. Grigsby J, Kaye K, Shetterley SM, Baxter J, Morgenstern NE, Hamman RF: Prevalence of disorders of executive cognitive functioning among the elderly: findings from the San Luis Valley Health and Aging Study. Neuropsychology 2002, 21:213-220.

16. Prevalence of disorders of executive cognitive functioning among the elderly: findings from the San Luis Valley Health and Aging Study. Neuropsychology 2002, 21:213-220.

17. Ruitenbergen A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM: Cerebral hypoperfusion and clinical stage of Alzheimer disease: evidence from an ultrasonographic study. J Neurol 2005, 252:559-563.

18. Silvestrini M, Pasqualetti P, Baruffaldi R, Bartolini M, Handouk Y, Bartolini M, Handouk Y, Matiea T, Mofta F, Provinciali L, Vrenieri F: Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 2006, 37:1010-1015.

19. Ameriso SF, Pagani-Hilli A, Meiselman HJ, Fisher M: Correlates of middle cerebral artery blood flow velocity in the elderly. Stroke 1990, 21:1579-1583.

20. Murphy DG, DeCarli C, McIntosh AR, Daly E, Mentis MJ, Piecini P, Szczepanik J, Schapiro MB, Grady CL, Horwitz B, Rapoport SI: Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch Gen Psychiatry 1996, 53:594-600.

21. Krajcova J, Mariak Z, Walecki J, Szydlki P, Lewko J, Ustymowicz A: Transcranial color Doppler sonography of basal cerebral arteries in 182 healthy subjects: age and sex variability and normal range values for blood flow parameters. AJR Am J Roentgenol 2006, 186:2165-2169.

22. Cavedoni R, Radice L, Ferrarini F, Longhini M, Longhini E: Influence of erythrocyte aggregability and plasma fibrinogen concentration on CBF with aging. Acta Neurol Scand 1992, 85:292-298.

23. Kazama K, Wang G, Frys K, Anrather J, Iadecola C: Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol 2005, 288:H1890-1899.

24. Cavanagh RD, Sorond FA, Vyas M, Gagnon M, Ilopuitafe ID, Lipkaita LS: Cerebral pressure-flow relations in hypertensive elderly humans: transfer gain in different frequency domains. J Appl Physiol 2003, 95:151-159.

25. Ander H, Zhou J, Macova M, Imboden H, Saavedra JM: Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004, 35:1726-1731.

26. Gard PR: The role of angiotensin II in cognitive and behaviour. Eur J Pharmacol 2002, 438:1-14.

27. Saavedra JM, Nishimura Y: Angiotensin and cerebral blood flow. Cell Mol Neurobiol 1999, 19:553-573.

28. Kazama K, Anrather J, Zhou J, Girouard H, Frys K, Milner TA, Iadecola C: Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004, 95:1019-1026.

29. Haber RL, Decker PJ, Einhaupl KM: Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arteries. Circ Res 1991, 68:1621-1627.

30. Dal-Ros S, Bronner C, Schott C, Kane MO, Chataigneau M, Schini-Kerth VB, Chataigneau T: Angiotensin II-induced hypertension is associated with a selective inhibition of endothelium-derived hyperpolarizing factor-mediated responses in the rat mesenteric artery. J Pharmacol Exp Ther 2009, 328:478-486.

31. Dimopoulou C, Chantepie Y, McClelland L, Yestek-Anacak G, Catrasas JD: Angiotensin, bradykinin and the endothelium. Handb Exp Pharmacol 2006, 229-249.

32. Khalil Z, LoGiudice D, Khodor B, Maruff P, Masters C: Impaired peripheral endothelial microvascular responsiveness in Alzheimer’s disease. J Alzheimers Dis 2007, 11:25-32.

33. Ghiadoni L, Virdis A: Aging and hypertension: what about the endothelium? J Hypertens 2006, 24:1243-1244.

34. Versari D, Daghini D, Virdis A, Ghiadoni L, Taddei S: The ageing endothelium, cardiovascular risk and disease in man. Exp Physiol 2009, 94:317-321.

35. Taddei S, Virdis A, Ghiadoni L, Versari D, Salvetti A: Endothelium, aging, and hypertension. Curr Hypertens Rep 2006, 8:84-89.

36. d’Alessio P: Aging and the endothelium. Exp Gerontol 2004, 39:165-171.

37. Padmanabhan N, Jardine AG, McGrath JC, Connell JM: Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007, 104:9108-9123.

38. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS, Hendrie H: Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002, 162:2090-2096.

39. Manolio TA, Olson J, Longstreth WT: Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep 2003, 5:255-261.

40. Roel F, Perez-Villa F, Morales J, Jimenez W, Orus J, Heras M, Sanz G: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53-57.

41. Carbonin P, Bernabei R: Use of angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation 1999, 99:2914-2920.

42. Tedesca MO, Ratti G, Menella S, Manzo G, Grieco M, Rainone AC, Larussi D, Iacono A: Comparison of losartan and hydrochlorothiazide on cognitive function. J Alzheimer’s Disease 1999, 2:213-218.

43. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.

44. Cummings JL, Cole G: Alzheimer’s disease. Jama 2002, 287:2335-2338.

45. Benjamin RH, Brandt J: Limitation of the Mini-Mental State Examination for the detection of amnesia. J Geriatr Psychiatry Neurol 1992, 5:233-237.

46. Pogosova GV, Zhidko NI, Ivanishina NS, Gudkova OA, Avakan GN: [Ramilpiril in elderly patients with mild and moderate hypertension. Clinical efficacy, effect on cerebral blood flow and intellectual functioning]. Kardiol Khirurgiya 1999, 43:42-47.

47. Zuccala G, Onder G, Marzetti E, Monaco MR, Cesari M, Cocchi A, Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A: Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005, 18:1052-1059.
53. Wagner C, Kramer BK, Hinder M, Kieninger M, Kurz A: T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol 1998, 124:579-585.

54. Nascimento L, Ayala JM, Baquerizo RA, Martinez-Maldonado M: Renin release by diuretics. J Pharmacol Exp Ther 1979, 208:522-526.

55. Di Bari M, Pahor M, Franse LV, Shorr RI, Witan JF, Ferrucci L, Somes GW, Appleyard WB: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEEP) trial. Am J Epidemiol 2001, 153:72-78.

56. Sadoshima S, Nagao T, Ibayashi S, Fujishima M: Inhibition of angiotensin-converting enzyme modulates the autoregulation of regional cerebral blood flow in hypertensive rats. Hypertension 1994, 23:781-785.

57. Dupuis F, Atkinson J, Liminana P, Chillon JM: Captopril improves cerebrovascular structure and function in old hypertensive Fischer 344 rats. Stroke 2000, 31:2478-2486.

58. Nishimura Y, Ito T, Saavedra JM: Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000, 31:2297-2303.

59. Yamaoka H, Hirayama M, Ando H, Saavedra JM: Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab 2003, 23:371-380.

60. Demuri B, MacKen P, Barylakutan U: Blockade of angiotensin II provides additional benefits in hypertension- and age-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 2005, 23:2219-2227.

61. Hatazawa J, Shimosegawa E, Otsuki Y, Ibaraki M, Oku N, Hasegawa S, Nagata K, Hirata Y, Muura Y: Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004, 35:2117-2122.

62. Lataste B, Garmagan H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM: Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002, 33:2297-2303.

63. Hatazawa J, Shimosegawa E, Otsuki Y, Ibaraki M, Oku N, Hasegawa S, Nagata K, Hirata Y, Muura Y: Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004, 35:2117-2122.

64. Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, Nomoto K, Kanemura S, Kobayashi S, Kurokawa T, et al: Angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 2005, 23:2219-2227.

65. Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, Nomoto K, Kanemura S, Kobayashi S, Kurokawa T, et al: Angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 2005, 23:2219-2227.

66. Randolph C, Tierney MC, Mold J, Scott JT, Adams RL: Age- and education-correlated independent normative data for the RBANS in a community dwelling elderly sample. Clin Neuropsychol 2003, 17:351-366.

67. Bis JC, Smith NL, Pasty BM, Heckbert SR, Edwards KL, Lemaitre RN, Lumley T, Rosendaal FR: Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003, 16:1011-1017.

68. Washburn RA, Ficker JL: Physical Activity Scale for the Elderly (PASE): the relationship with activity measured by a port-a- accelerometer. J Gerontol 1998, 53:M43-M49.

69. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.

70. Kurz TW, Griffith KA, Bidani AK, Davison RL, Hall JE: Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hyper Pressure 2005, 45:299-310.

71. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hall MN, Jones DW, Kurz T, Sheps SG, Roccella EJ: Recommendations for blood pressure measurement in humans and experimental animals: Part I: Blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2002, 40:2117-2122.

72. Dicpinigaitis PV: “Mini-state”. A practical method for grading the cognitive state of patients for the clinician. J Hypertens (Greenwich) 1995, 13:189-198.

73. Hatazawa J, Shimosegawa E, Otsuki Y, Ibaraki M, Oku N, Hasegawa S, Nagata K, Hirata Y, Muura Y: Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004, 35:2117-2122.
94. Diggle P, Liang K, Zeger S: Analysis of Longitudinal Data. Oxford University Press; 1994.
95. McCullagh P, Nelder J: Generalized Linear Models. London.: Chapman and Hall; 1987.
96. Nilsson SE, Read S, Berg S, Johansson B, Melander A, Lindblad U. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res 2007, 19:41-47.
97. Kilander L, Nyman H, Boberg M, Lithell H. The association between low diastolic blood pressure in middle age and cognitive function in old age. A population-based study. Age Aging 2000, 29:243-248.
98. Axelsson J, Reinprecht F, Siennicki-Lantz A, Elmstahl S. Low ambulatory blood pressure is associated with lower cognitive function in healthy elderly men. Blood Press Monit 2008, 13:269-275.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2318/9/48/prepub